Barclays analyst Matt Miksic maintains $Tandem Diabetes Care (TNDM.US)$ with a buy rating, and adjusts the target price from $58 to $60.
According to TipRanks data, the analyst has a success rate of 62.0% and a total average return of 7.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Tandem Diabetes Care (TNDM.US)$'s main analysts recently are as follows:
Tandem Diabetes has reported another strong growth quarter, prompting an increase in its full-year growth guidance to 17%-18%. This performance is primarily attributed to the ongoing success of the Mobi launch.
In spite of delivering yet another quarter of surpassing expectations and elevating future guidance, the third in a series, shares experienced a downturn. The cause of this market reaction is attributed to the persistent uncertainty regarding the strength of future growth drivers. The perception is that the company has made a decisive positive shift, with the anticipation that foundational aspects will progressively enhance. Nevertheless, a cautious stance is being maintained pending greater assurance in the enduring factors that will propel sales growth.
Analysts noted that Tandem Diabetes' Q3 revenue surpassed expectations, although partial contributions came from timing benefits related to U.S. supplies and international distributor orders. They observed that Q3 pump shipments in the U.S. aligned closely with their projections.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克萊銀行分析師Matt Miksic維持$Tandem Diabetes Care (TNDM.US)$買入評級，並將目標價從58美元上調至60美元。
根據TipRanks數據顯示，該分析師近一年總勝率為62.0%，總平均回報率為7.5%。
此外，綜合報道，$Tandem Diabetes Care (TNDM.US)$近期主要分析師觀點如下：
Tandem Diabetes報告了又一個強勁增長的季度，促使其全年增長預期上調至17％-18％。 這一業績主要歸功於Mobi推出的持續成功。
儘管交付了再次超越預期並提升未來指引的又一個季度，這是一個系列中的第三個，但股價卻出現了下跌。 這種市場反應的原因歸因於對未來增長驅動因素實力的持續不確定性。 普遍看法認爲，公司已經做出了積極的決定性轉變，預期基礎方面將逐步增強。 儘管如此，人們仍在持謹慎態度，等待更大的保證，這些保證將推動銷售增長。
分析師指出，Tandem Diabetes的第三季度營業收入超出預期，儘管部分貢獻來自於美國供應和國際分銷商訂單相關的時機收益。 他們觀察到第三季度美國的泵裝運量與他們的預測接近。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
